# Sundar Jagannath

Source: https://onco.cc/people/sundar-jagannath/  
OnCo record `sundar-jagannath` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Veteran myeloma trialist who helped bring proteasome inhibitors and bispecifics to patients.

## Summary

Sundar Jagannath is Director of the Center of Excellence for Multiple Myeloma at The Mount Sinai Hospital and Tisch Cancer Institute. He is a veteran myeloma trialist who helped bring proteasome inhibitors and bispecific antibodies to patients, serving as principal investigator across bortezomib, carfilzomib and teclistamab-era studies. His selected paper reports bortezomib alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. He directs Mount Sinai's myeloma centre and continues to work on novel agents and bispecific antibodies.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Center of Excellence for Multiple Myeloma
- Specialisms: Multiple myeloma; Novel agents; Bispecific antibodies

## Sources

- Mount Sinai profile: https://profiles.mountsinai.org/sundar-jagannath
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Jagannath%20S%5BAuthor%5D

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Bortezomib](https://onco.cc/drugs/bortezomib/), [Carfilzomib](https://onco.cc/drugs/carfilzomib/), [Teclistamab](https://onco.cc/drugs/teclistamab/)
- institutions: [The Mount Sinai Hospital / Tisch Cancer Institute](https://onco.cc/institutions/mount-sinai/)

---
JSON: https://onco.cc/api/v1/entities/sundar-jagannath.json